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Background: Glatiramer acetate (GA) and interferon-beta (IFN-β) are disease-modifying therapies (DMTs) for
multiple sclerosis that are administered through subcutaneous (SC) or intramuscular (IM) injections. Skin reactions
associated with DMTs are common and may influence patient’s health-related quality of life (QoL). We aimed to
determine the prevalence of cutaneous adverse events associated with long-term DMT use, and to assess the
impact of cutaneous adverse events on QoL.
Methods: A cross-sectional study among patients with multiple sclerosis who had been treated with their first DMT
for at least 2 years. Cutaneous events were assessed from photographs of injection-sites by dermatologists blinded
for DMT. Generic and dermatology-specific health-related QoL were assessed using validated patient-reported
questionnaires.
Results: A total of 229 patients were enrolled, of whom 156 (68%) had at least one skin reaction. The prevalence of
cutaneous adverse events was higher for SC DMTs (75-82%) compared to IM DMT (41%) (P < 0.001). Erythema and
lipoatrophy were the most common skin reactions, observed in 156 (68%) and 45 (20%) patients, respectively.
Dermatology-specific, but not generic, QoL was significantly lower among patients with skin reactions compared to
those without.
Conclusions: The prevalence of cutaneous adverse events was high in long-term DMT-treatment. Patients with
cutaneous adverse events had a lower perceived dermatology-specific QoL.
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Multiple sclerosis (MS) is an immune-mediated inflam-
matory disease of the central nervous system that is
characterized by inflammation, demyelination, and
neurodegeneration within the brain and the spinal cord
[1]. Most cases present as relapsing-remitting MS that
eventually progresses to a secondary progressive stage* Correspondence: d.balak@erasmusmc.nl
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reproduction in any medium, provided the or[2]. Treatment of MS is currently limited to reducing
disease progression via disease-modifying treatments
(DMTs) that modulate the immune system [3]. Ap-
proved first-line DMTs are glatiramer acetate (GA) and
interferon-β (IFN-β), which require self-administration
via subcutaneous (SC) or intramuscular (IM) injections.
To date, four first-line injectable DMTs are approved
for the treatment of MS: SC GA (Copaxone), which is
injected once daily; SC IFN-β-1b (Betaferon/Betaseron)
injected once every other day; SC IFN-β-1a (Rebif )d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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injected once a week.
GA and IFN-β have been used for more than a decade,
and their efficacy and safety-profile are well documented
[3]. Skin reactions appear to be frequently occurring
adverse events during DMT treatment. A systematic
review from 2012 reported relatively high prevalences of
cutaneous adverse events associated with DMT, with up
to 90% for patients treated with a SC DMT and up to 33%
among those treated with an IM DMT [4]. The majority
of the reported cutaneous adverse events comprise local
injection-site reactions such as erythema, swelling, and
induration of the skin surrounding the injection-site.
These skin reactions are usually mild and do not neces-
sitate discontinuation of treatment. Other cutaneous
adverse events may be more severe or persisting, such
as lipoatrophy, cutaneous necrosis and ulcers, and inflam-
matory skin diseases like psoriasis and vasculitis [4].
Despite the high frequency of cutaneous adverse
events associated with DMT, relatively little is known
about their impact of patient’s quality of life during
long-term treatment.
In this cross-sectional study, we aimed to determine
the prevalence of cutaneous adverse events associated
with long-term treatment with DMT in daily clinical
practice, to assess the effects of cutaneous adverse
events on patient’s quality of life, and to identify factors
associated with the occurrence of skin reactions.
Methods
Study design
The Dermatological injection site reactions in Multiple
Sclerosis (derMiS) study was a cross-sectional study
conducted among 15 neurology outpatient clinics in the
Netherlands. The study was conducted in the period
December 2010 to September 2011. The local medical
ethical review committees of the Catharina Ziekenhuis
(Eindhoven, the Netherlands) and the Central Committee
on Research involving Human Subjects (The Hague, the
Netherlands) approved the study protocol. All patients
gave written informed consent.
Study population
Inclusion criteria allowed inclusion of patients who were
diagnosed with relapsing-remitting MS or clinically iso-
lated syndrome suggestive of MS and who were treated
with their first DMT for 2 years or longer. The DMT
considered in this study were SC GA, SC IFN-β-1a, IM
IFN-β-1a, and SC IFN-β-1b. Patients were excluded if
they were treated with their first DMT for less than 2
years, or if they had switched previously from another
DMT. In order to prevent selection bias, all consecutive
patients willing to participate were included, irrespective
of the presence of skin reactions at the injection site.Data collection
All data were collected at a single study-visit. Clinical
data that were collected were age, sex, weight, length,
atopy status, year of onset of MS, type of DMT, treatment
duration of DMT, injection-site locations, and concomi-
tant injectable treatments for diseases other than MS. The
occurrence of skin reactions as assessed by the treating
neurologist and by patients themselves was recorded.
Further, digital photographs were taken of all injection-
sites of each patient, with both a close-up and an overview
photograph of each injection-site. All digital photographs
were centrally assessed for the occurrence and extent of
cutaneous adverse events by dermatologists, who were
blinded with respect to the DMT treatment-arm. Cutane-
ous adverse events were defined as any skin abnormality
that was assessed on the digital photographs. Several
cutaneous adverse events were predefined prior to
assessing the photographs, including erythema, ec-
chymosis, lipoatrophy, panniculitis, skin necrosis, and
skin ulcer.
Patients’ attitudes towards injection-site reactions were
recorded using a patient-reported questionnaire. Quality
of life was assessed using validated patient-reported
questionnaires. Generic health-related quality of life (QoL)
was measured using the European Quality of life question-
naire 5 Dimensions (EQ-5D) questionnaire [5]. The EQ-
5D uses two scoring systems, with higher scores indicating
better QoL. The EQ-5D descriptive system evaluates 5
dimensions (mobility, self-care, usual activities, pain/
discomfort and anxiety/depression) in a utility-index of
0 to 1.0. The EQ-5D visual analogue scale (VAS)
records patient’s self-rated health on a scale of 0 to 100.
Dermatological-specific health-related QoL was measured
using the Skindex-17 questionnaire [6]. The Skindex-17
consists of two domains: a psychosocial domain on a
scale from 0 to 24, and a symptoms domain on a scale
from 0 to 10. Higher Skindex-17 scores indicate lower
QoL.
Data analysis
Data were analysed using descriptive statistical methods.
Data are presented as means and standard deviation
(SD), or as medians and interquartile range (IQR) when
not normally distributed. Differences in categorical vari-
ables and continuous variables between the groups were
tested with the Kruskal Wallis test or the Chi square
test, respectively. We did not correct for multiple test-
ing, considering that valid associations would be missed
otherwise [7]. The associations between putative deter-
minants and the occurrence of cutaneous adverse events
were assessed by calculating odds ratio (OR) and 95%
confidence intervals (CI) using logistic regression. A
P-value of 0.05 or less was considered statistically
significant.
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Study population
A total of 229 patients were enrolled. Patient characteris-
tics are presented in Table 1. The majority (73%) of the
patients were female, and the median age at time of enrol-
ment was 48 years (IQR 41–54 years). Median duration of
MS was 9 years (IQR 4–16 years), and median duration of
the DMT-treatment was 5 years (IQR 3–9 years). Forty-
four (19%) patients were treated with GA, 60 (26%) with
IFN-β-1b, 66 (29%) with SC IFN-β-1a, and 59 (26%) with
IM IFN-β-1a. Age of time of enrolment and use of an
auto-injector for DMT-administration differed between
the four DMT-groups. There were no statistically signifi-
cant differences in the other demographic or clinical
variables.Prevalence of cutaneous adverse events
Of all 229 patients, 156 (68%) had at least one cutaneous
adverse event as assessed on the digital photographs by
the dermatologists (Figure 1). Patients treated with once
weekly IM IFN-β-1a had the lowest frequency of cutane-
ous adverse events, with skin reactions found in 24 (41%)
of 59 patients (P < 0.001 vs. other frequently administrated
DMTs). The prevalence of cutaneous adverse events in
the SC DMT-groups was comparable, ranging from
75% for GA and for SC IFN-β-1b to 82% for SC IFN-β-
1a (P = 0.624). The prevalence of cutaneous adverse
events in the SC IFN-β-1b group was not statistically dif-
ferent from those treated with SC IFN-β-1a (P = 0.352).
The prevalence of patient self-reported cutaneous adverse
events was comparable to that as assessed by the dermatol-
ogists (Figure 1). Only in the group of IM IFN-β-1a, the
prevalence of skin reactions as self-reported by patients was
smaller compared to the prevalence of skin reactions as
assessed by the dermatologists. The prevalences of skin
reactions reported by the treating neurologists were
consistently lower compared to the dermatologists- and
patient-reported prevalences.Table 1 Patient characteristics
Disease-mod
GA SC IFN-β-1b
No. of patients 44 (19%) 60 (26%)
Age in years at time of enrolment 48 (40–54) 51 (44–58)
No. of female patients 37 (84%) 40 (67%)
Body mass index in kg/m2 25 (22–27) 25 (23–27)
Duration of MS in years 8 (4–17) 11 (4–17)
Duration of DMT in years 5 (3–8) 5 (3–12)
Use of auto-injector for injections of DMT 33 (75%) 52 (87%)
Data are presented as medians (interquartile range) or numbers (percentages).
Abbreviations: GA glatiramer acetate, IFN interferon, IM intramuscular, MS multiple s
*Differences between the groups were tested with the Kruskal Wallis test or the ChType of cutaneous adverse events
Overall, erythema and lipoatrophy were the most common
skin reactions, which were observed in 156 (68%) and 45
(20%) patients, respectively (Table 2). Less frequently
occurring cutaneous reactions were postinflammatory
hyperpigmentation (7%), eczema-like reactions (6%), healed
scars (3%), urticaria (2%), skin necrosis (0.4%), varicose
veins (0.4%), and subcutaneous swelling (0.4%). Figure 2
shows examples of erythema, eczema-like reaction,
lipoatrophy, and a healed scar with postinflammatory
hyperpigmentation.
Erythema was the most common skin reaction in all
four DMT-groups. The group treated with IM IFN-β-1a
had a lower proportion of erythema (19%) in compari-
son to the other three DMTs (46% to 79%) (P < 0.001,
IM IFN-β-1a vs. the other DMTs). The second-most
reported skin reaction was lipoatrophy, which was
reported mostly in patients treated with GA. Fifteen
(34%) of 44 patients on SC GA were diagnosed with
lipoatrophy, which was significantly higher compared to
the proportion of lipoatrophy among patients treated
with SC IFN-β-1b (17%), SC IFN-β-1a (17%), and IM
IFN-β-1a (15%) (P = 0.007, GA vs. the other three DMTs).
Frequencies of ecchymosis were roughly comparable be-
tween the 4 DMTs. By contrast, postinflammatory hyper-
pigmentation was found predominantly in patients treated
with SC IFN-β-1b (11%) and GA (11%), compared to
patients on SC IFN-β-1a (5%) and on IM IFN-β-1a (0%)
(P = 0.02, IM IFN-β-1a vs. the other 3 DMTs). The pro-
portion of eczema was higher in patients treated with
SC IFN-β-1b (13%), compared to those treated with SC
IFN-β-1b (6%), IM IFN-β-1a (2%), and GA (2%) (P = 0.011,
SC IFN-β-1b vs. the other DMTs). Cutaneous ulcers were
predominantly described in patients treated with GA (11%),
whereas the prevalence was lower among patients treated
with SC IFN-β-1a (2%), SC IFN-β-1b (0%), and IM IFN-β-
1a (0%) (P = 0.003, GA vs. other DMTs). The other cutane-
ous adverse events occurred too infrequently to assess
differential prevalences between the four DMTs.ifying therapy for MS
SC IFN-β-1a IM IFN-β-1a Total group P-value*
66 (29%) 59 (26%) 229 (100%)
45 (40–52) 49 (41–55) 48 (41–54) 0.025
46 (70%) 45 (76%) 168 (73%) 0.197
25 (23–27) 25 (22–27) 25 (23–27) 0.871
7 (3–13) 10 (4–14) 9 (4–16) 0.192
4 (3–8) 5 (4–10) 5 (3–9) 0.177
49 (74%) 18 (31%) 152 (66%) < 0.001
clerosis, SC subcutaneous.
i square test.
once daily once every other day three times a week once a week 
Figure 1 Prevalence of cutaneous adverse events per DMT as reported by dermatologists (black bars), by patients themselves (white bars),
and by the treating neurologists (grey bars).
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Generic QoL as measured by EQ-5D did not differ sub-
stantially between patients with and without skin reactions
(Table 3). Both the EQ-5D utility score and the EQ-5D
VAS were comparable between patients with cutaneous
adverse events and patients without cutaneous adverse
events.
In contrast, dermatology-specific QoL was significantly
lower among patients with cutaneous adverse events.
The mean (SD) Skindex-17 psychological score was 2.2
(3.0) among the patients with cutaneous adverse events,
which was significantly higher in comparison to the
group without cutaneous adverse events (mean score 1.0
(SD 2.2)) (P < 0.001). Likewise, the mean (SD) Skindex-
17 symptom score was relatively high in the group with
cutaneous adverse events than compared to patients
without cutaneous adverse events (2.1 (1.7) vs. 1.5 (1.5);
P = 0.002).
Although patients with cutaneous adverse events had sig-
nificantly higher Skindex-17 psychological and symptomsTable 2 Frequencies of different types of cutaneous adverse e
Disease-mod
GA (n = 44) SC IFN-β-1b (n = 60)
Erythema 20 (46%) 39 (65%)
Lipoatrophy 15 (34%) 10 (17%)
Ecchymosis 4 (9%) 7 (12%)
Postinflammatory hyperpigmentation 5 (11%) 7 (11%)
Eczema 1 (2%) 8 (13%)
Healed ulcers 5 (11%) 0 (0%)
Urticaria 0 (0%) 3 (5%)
Necrosis 0 (0%) 1 (2%)
Varicose veins 0 (0%) 0 (0%)
Subcutaneous swelling 0 (0%) 0 (0%)
Abbreviations: DMT disease-modifying treatment, GA glatiramer acetate, IFN interferscores than did patients without cutaneous adverse events,
the proportion of patients with a severe impairment of
QoL was relatively small. Only 10 (4%) patients had high
Skindex-17 psychosocial score indicating a severe impair-
ment of their QoL. Eighteen (8%) patients had high
Skindex-17 symptoms scores indicating a large impact on
their QoL.
In a subgroup analysis we did not find any association
between specific cutaneous adverse events and lower
QoL (data not shown).
Patients’ attitudes towards cutaneous adverse events
A majority (58%) of all 299 patients felt it was important
that their MS treatment did not lead to cutaneous
adverse events, whereas 73 (32%) patients felt it was of
little importance, and 23 (10%) patients felt it was not
important. Of the 126 patients who reported to have cu-
taneous adverse events to their DMT, 24 (19%) patients
indicated the cutaneous reactions to be very cosmetic-
ally disfiguring, 29 (23%) to be disfiguring, and 52 (41%)vents per DMT
ifying therapy for MS
SC IFN-β-1a (n = 66) IM IFN-β-1a (n = 59) Total group (n = 229)
52 (79%) 11 (19%) 156 (68%)
11 (17%) 9 (15%) 45 (20%)
6 (9%) 4 (7%) 21 (9%)
3 (5%) 0 (0%) 15 (7%)
4 (6%) 1 (2%) 14 (6%)
2 (3%) 0 (0%) 7 (3%)
1 (2%) 0 (0%) 4 (2%)
0 (0%) 0 (0%) 1 (0.4%)
0 (0%) 1 (2%) 1 (0.4%)
0 (0%) 1 (2%) 1 (0.4%)
on, IM intramuscular, MS multiple sclerosis, SC subcutaneous.
A B 
D C 
Figure 2 Examples of different types of cutaneous adverse events: erythema (panel A), lipoatrophy (panel B), eczema-like reaction
(panel C), and postinflammatory hyperpigmentation and healed scar (panel D).
Balak et al. BMC Neurology 2013, 13:146 Page 5 of 8
http://www.biomedcentral.com/1471-2377/13/146and 21 (17%) indicated the cutaneous reactions to be a
little disfiguring or not disfiguring at all, respectively.
Most patients (77%) reported that cutaneous reactions
did not influence their choice of clothing, while 15
(12%) and 14 (11%) patients reported a large to a very
large influence of cutaneous reactions on their choice of
clothing, respectively. Twenty-four (19%) patients indicatedTable 3 Self-reported generic (EQ-5D) and dermatology-speci
with and without cutaneous adverse events associated with D
Yes (n = 156)
Generic quality of life
EQ-5D utility
median (IQR) 0.727 (0.620–0.848
mean (SD) 0.725 (0.205)
EQ-5D VAS
median (IQR) 70.0 (60.0–80.0)
mean (SD) 67.3 (20.9)
Dermatology-specific quality of life
Skindex-17 Psychosocial
median (IQR) 1 (0–3)
mean (SD) 2.2 (3.0)
Skindex-17 Symptoms
median (IQR) 2 (1–3)
mean (SD) 2.1 (1.7)
*Differences between patients with and without cutaneous adverse events were testhat cutaneous reactions greatly impacted their overall
contentment with the DMT, 41 (33%) indicated a little
impact, and 61 (48%) indicated that cutaneous reactions
did not impact their overall contentment of their DMT.
Finally, 9 (4%) patients reported to have missed injec-
tions of their DMT in the past because of cutaneous
adverse events.fic (Skindex-17) health-related quality of life in patients
MT
Cutaneous adverse events
No (n = 73) P value*
) 0.718 (0.664–0.814) 0.779
0.714 (0.218)
75.0 (60.0–80.5) 0.361
71.7 (15.8)
0 (0–1) P < 0.001
1.0 (2.2)
1 (0–2) 0.002
1.5 (1.5)
ted with the Chi square test.
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We assessed the associations between the occurrence of
local injection-site reactions and lipoatrophy with four
putative determinants: atopy, use of auto-injector, sex,
and body mass index. None of these 4 factors were
statistically significantly associated with the occurrence
of cutaneous adverse events (Table 4). There was a trend
that female sex was associated with the occurrence of
lipoatrophy, however, this association was not statistically
significant.
Discussion
In this cross-sectional study among 229 MS patients
treated with their first DMT for at least 2 years, 156
(68%) patients were diagnosed with a cutaneous adverse
event, with erythema and lipoatrophy being the most
common occurring cutaneous events. Patients with a cuta-
neous adverse event appeared to have a lower dermatology-
specific, but not generic, health-related quality of life as
compared to those without a cutaneous adverse event.
To appreciate these findings, several limitations need
to be considered. First, we included patients who were
treated with their first DMT continuously for a treat-
ment period of at least 2 years. Patients who experienced
severe cutaneous adverse events to their DMT or patients
who experienced cutaneous adverse events as bothersome
are likely to have discontinued their treatment and
switched to another DMT before 2 years of treatment.
Second, our study is based on cross-sectional data. Con-
sidering that the frequency of administration differs
between the 4 DMTs, the time periods between the
moment of last DMT-injection and the moment of the
photograph will be different for the 4 DMTs. This may
affect the assessment of in particular passing and transi-
ent skin reactions such as erythema. Consequently, this
may introduce a bias, leading to either under- or over-
reporting of cutaneous adverse events. Finally, we
assessed skin reactions from digital 2-D photographs.
Considering that we did not have 3-D photographs
available, there may have been underreporting of mild
cases of lipoatrophy presenting with subtle skin depres-
sions. The main strengths of this study are its large sam-
ple size, that skin reactions associated with DMTs wereTable 4 Putative factors associated with local injection-site re
Local injection-site reactions*
Odds ratio 95% CI
Atopy 1.14 0.59–2.21
Use of auto-injector 1.45 0.80–2.64
Sex 0.88 0.46–1.68
Body mass index 1.00 0.94–1.07
*Local injections-site reactions include erythema, ecchymosis, and subcutaneous swthe primary outcome, and that the assessment of the
skin reactions were done by dermatologists blinded for
the treatment. Furthermore, we only included patients
who used one type of DMT making it possible to caus-
ally link type of DMT to the adverse skin reactions.
Our results demonstrate that in daily clinical practice
long-term DMT-use is associated with a high frequency
of cutaneous adverse events up to 68% of patients. These
results are in line with previous studies, in which the fre-
quency of skin reactions to DMT seem equally high. In
an observational prospective multicentre study from
Switzerland, 214 (52%) of 412 MS patients had a skin
reaction to their DMT [8]. Furthermore, after a one-year
follow up period 10% of these patients had developed
lipoatrophy, while 3% had developed skin necrosis.
Local injection-site reactions as erythema appear to be
dependent on the mode of administration, because the
subcutaneous DMTs are in particular associated with
erythema, while patients treated with once weekly intra-
muscular DMT had the lowest prevalence of erythema.
By contrast, the occurrence of lipoatrophy seems to be
associated with the DMT rather than with mode of ad-
ministration. GA was associated with the highest preva-
lence of lipoatrophy, while the three IFN-formulations
had relatively few reports of lipoatrophy. This observation
is in line with previous reported cases of lipoatrophy
with DMT-use, in which most cases involved patients
treated with GA [4]. However, an unexpected finding was
lipoatrophy occurring in 15% of patients on IM IFN-β-1a.
The occurrence of lipoatrophy in patients on IM IFN-β-1a
may be explained by an incorrect injection-site technique
with subcutaneous instead of intramuscular administra-
tion [9].
In this study, generic health-related quality of life as
measured by EQ-5D was not affected by the occurrence
of skin reactions. By contrast, dermatology-specific health-
related quality of life was substantial lower among patients
who were diagnosed with cutaneous adverse events. How-
ever, the proportion with severe impairment was relatively
low, even for patients with lipoatrophy, which in general is
an irreversible and often cosmetic disfiguring cutaneous
adverse event. This low impact on health-related quality
of life may be explained by the design and the inclusion-actions and lipoatrophy
Lipoatrophy
P-value Odds ratio 95% CI P-value
0.692 1.17 0.55–2.49 0.691
0.219 1.01 0.49–2.07 0.977
0.690 0.41 0.16–1.03 0.058
0.898 0.98 0.91–1.06 0.629
elling.
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events resulting in a reduced quality of life may have
stopped their specific treatment within the first two years
of treatment, thus making them not eligible to participate
in this study.
Several studies have shown that skin reactions are
associated with a reduced treatment adherence to DMT.
Severe and persisting skin reactions may lead to loss of
quality of life, which may also lead to reduced adherence
to DMT [10,11]. Previous studies have shown that a
reduced treatment adherence to DMT is associated with
suboptimal treatment outcomes [12,13], making skin re-
actions associated with DMTs clinically relevant for the
treating neurologists. In a retrospective study among
643 MS patients, skin reactions were a reason for non-
adherence to their DMT in 9% of all patients [14]. In an
observational prospective study among 414 MS patients
treated with a DMT for at least 2 years, more than half
(52%) of all patients were diagnosed with a skin reaction,
while patients reported injection-site reactions as the
most common reason for wanting treatment discontinu-
ation [8]. In our study, a small proportion (4%) of patients
reported to have missed injections because of skin
reactions. This may be explained by the low impact of
cutaneous adverse events on health-related quality of
life in the studied population.
An interesting finding in this study is that the treating
neurologists reported consistently lower prevalences of
cutaneous adverse events compared to the dermatologists,
emphasising that skin reactions seem to be underrecognized
by neurologists. Treating neurologists should probably
question patients more carefully for cutaneous adverse
events and pay attention to these specific side effects
during their physical examination.
Conclusions
In conclusion, our results show that cutaneous adverse
events are common with long-term DMT treatment,
that cutaneous reactions mostly involve local injection-
site reactions and lipoatrophy, and that cutaneous ad-
verse events somewhat lowers dermatologic-specific
health-related quality of life of patients with MS who
have been treated for over two years with an injectable
DMT.
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